switching from dulaglutide to semaglutide GLP-1 dose conversion chart and safe guide difference between dulaglutide and tirzepatide

Efficacy and Safety of Semaglutide 7.2 mg in Obesity: The STEP UP Trial

Yes, through the Medicare GLP-1 Bridge Program starting July 1, 2026

Common side effects: Nausea, vomiting, constipation or diarrhoea: usually worst when starting and after each dose increase, and usually improves with time

NICE guidance (NG7 and TA875) emphasises the importance of dietary support alongside pharmacological interventions for obesity management, and healthcare professionals typically provide patients with practical eating strategies when prescribing GLP-1 receptor agonists

Compounded GLP 1 pharmacies are in a fight for survival

Damages lipid membranes, denatures proteins, and impairs receptor function